BioSpace News Archive

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,576,111, entitled “Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH).

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.

US-based supply chain mitigates coronavirus-related disruption risks

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for fourth quarter and full-year 2019 and business update on Thursday, March 12, 2020.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that the United States Patent and Trademark Office (USPTO) issued the Company its first U.S. patent related to the DecisionDx®-Melanoma gene expression profile test for patients with cutaneous melanoma

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that data from the interim analysis of Piclidenoson in its Phase III clinical study is expected to be released during Q4 2020.

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2019, and provided an outlook for 2020.

Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the hiring of Gretchen Gary as Vice President of Global Therapy Development.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that the first patient has begun treatment in the third and final cohort of the Actimab-A CLAG-M combination trial.